---
title: "BOJI CRO: Passed the GLP certification review and obtained the \"Drug GLP Certification Certificate\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227199626.md"
description: "BOJI CRO recently obtained the \"Drug GLP Certification\" issued by the National Medical Products Administration, with certificate number GLP039010219, successfully passed the GLP certification review, and possesses 8 certification qualifications. This certification is valid until January 22, 2030, indicating that the company meets the requirements of the quality management standards for non-clinical research of drugs, which helps the company undertake non-clinical safety evaluation business and enhance its new drug research and development service capabilities"
datetime: "2025-02-05T10:55:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227199626.md)
  - [en](https://longbridge.com/en/news/227199626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227199626.md)
generator: "portal-rs"
---

# BOJI CRO: Passed the GLP certification review and obtained the "Drug GLP Certification Certificate"

BOJI CRO announced that the company recently received a new "Drug GLP Certification" issued by the National Medical Products Administration, with the certificate number GLP039010219. The company successfully passed the GLP certification re-examination and obtained the "Drug GLP Certification," with a total of 8 certification qualifications. The specific institution conducting non-clinical safety evaluation research for drugs is BOJI CRO Technology Co., Ltd. Drug Evaluation Center, located at Building 62, Nanxiang 1st Road, Science City, Huangpu District, Guangzhou. The testing projects include single and repeated dose toxicity tests, reproductive toxicity tests, genetic toxicity tests, local toxicity tests, immunogenicity tests, safety pharmacology tests, and toxicokinetics tests. The certification conclusion states that the company meets the requirements of the quality management standards for non-clinical research of drugs, valid until January 22, 2030. This successful GLP certification re-examination is beneficial for the company to undertake non-clinical safety evaluation business externally and continuously strengthen its ability to provide one-stop services for new drug research and development to clients

### Related Stocks

- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)
- [GLP.US](https://longbridge.com/en/quote/GLP.US.md)

## Related News & Research

- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [08:18 ETLuminar Capital Closes $5 Million Senior Secured Credit Facility, Scalable to $15 Million](https://longbridge.com/en/news/296227261.md)
- [CASAN corrects board minutes to refer to public note issuance via Banco Bocom BBM](https://longbridge.com/en/news/296411185.md)
- [Uzbekistan Hosts 38th International Olympiad in Informatics, Cementing Role as Central Asia’s Leading IT Hub](https://longbridge.com/en/news/296140590.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**